Orthofix Medical (OFIX) CG 2025 Musculoskeletal Conference summary

Key business and conference highlights

• Achieved strong Q4 and full-year growth, with all business segments outpacing the market and EBITDA increasing faster than revenue.

• Q4 2024 net sales reached $215.7M (8% YoY growth), with 2024 net sales at $799.5M, up 7.1% YoY; U.S. represented 84% of sales.

• Generated $21 million in free cash flow in Q2 2024, with full-year free cash flow totaling $47.98M, reversing a previous negative position of over $100 million in 2023.

• Adjusted EBITDA for 2024 was $67.4M, with Q4 adjusted EBITDA at $23.9M (11.1% margin); EBITDA margins improved by over 200 basis points.

• Ended 2024 with $85 million in cash and a $275 million credit facility, improving liquidity by $50 million year-over-year.

Strategic initiatives and portfolio management

• Discontinued the M6-C product and other underperforming orthopedic lines to focus on areas with competitive advantage.

• No further divestitures planned; focus is on building a strong foundation in enabling technologies and redefining lumbar reconstruction.

• Long-range plan targets 6.5%-7.5% net sales growth and 300 basis points of gross margin expansion by 2027, with mid-teens adjusted EBITDA margin.

• EBITDA and free cash flow improvements expected to be stepwise, with significant gains back-end loaded into 2026 and 2027.

• Focused on margin expansion through cost leverage, merger synergies, and operational discipline.

Commercial and operational strategy

• Enhanced commercial focus by leveraging a broad portfolio and creating multiple access points in accounts.

• Shifted to larger, exclusive distributors in spine, and redefined the mission in orthopedics to accelerate growth.

• Improved inventory management and direct commercial control in bone growth therapies, with over 50% of sales direct.

• Targeting improved working capital efficiency, inventory management, and instrument utilization.

• U.S. Orthopedics, Spine Fixation, and Bone Growth Therapies all delivered double-digit YoY net sales growth in Q4.